John Ladetto, MD
Pulmonary Disease · Riverside, RINPI 1447217641
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $36,348 of the $38,900 with a category attached, or 93.4%. Boehringer Ingelheim accounts for 73.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2019 at $30,303 and has fallen 99.6% since, to $125 in 2024. Among pulmonary disease clinicians in RI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $694.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$29K
- Regeneron Healthcare Solutions, Inc.$10K
- AstraZeneca$263
- Actelion Pharmaceuticals US, Inc.$250
- GSK$127
What the payments were for
- Consulting fees$4301%
- Speaking & faculty fees$36,34893%
- Travel & lodging$2051%
- Food & beverage$1,8975%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 22 | $28,607 |
| Regeneron Healthcare Solutions, Inc. | 10 | $9,653 |
| AstraZeneca | 4 | $263 |
| Actelion Pharmaceuticals US, Inc. | 18 | $250 |
| GSK | 2 | $127 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$9,280
- OFEV$7,868
- FASENRA$243
- TRELEGY ELLIPTA$105
How this compares
$38,900 in reported general payments places this provider in the 90th percentile of 59 pulmonary disease providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 548 | $387,229 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 139 | $102,097 |
| Spiriva RespimatTiotropium Bromide | 126 | $67,319 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 135 | $61,922 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 112 | $58,116 |
| XolairOmalizumab | 16 | $54,249 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 165 | $49,493 |
| NucalaMepolizumab | 12 | $46,290 |
| SymbicortBudesonide/Formoterol Fumarate | 88 | $26,880 |
| Breo ElliptaFluticasone/Vilanterol | 61 | $25,963 |
| Arnuity ElliptaFluticasone Furoate | 98 | $22,591 |
| Incruse ElliptaUmeclidinium Bromide | 31 | $16,111 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 79 | $15,460 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 398 | $12,436 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $12,161 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta | $127 | $560,106885 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $263 | $128,976227 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $28,607 | $125,435238 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 59 pulmonary disease providers in Rhode Island.
Other pulmonary disease in Riverside
- Corey VentetuoloRiverside$51K
- Douglas MartinRiverside$4K
- James KlingerRiverside$3K
- Matthew BallenbergerRiverside$1K
- Peter KarczmarRiverside$245
- Ronald GilmanRiverside$136
- James MyersRiverside$136
- Seema AminRiverside$110
- Michael BlundinRiverside$100
- E Jane CarterRiverside$75
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.